Current interventions for endometriosis mainly involve hormone therapies but have limited efficacy and unacceptable side effects due to the lack of selectivity to distinguish between endometriosis and endometrial tissues. Elucidating …
Medical therapy is crucial in the long-term management of endometriosis, and its clinical efficacy must be balanced with a favorable safety profile.
Limited research has examined psychological treatments for endometriosis-related chronic pain, despite its association with elevated disability, depression, and anxiety. Remotely delivered treatments have the potential to overcome barriers to access …
Menstrual blood (MB), a biofluid rich in diverse cell types and biomolecules, has emerged as a vital resource for investigating female reproductive health and diseases because of its unique composition …
Endometriosis is a chronic gynecologic disease that needs newer and safer treatments. The proposed work aims to develop a nanosystem based on gold nanoparticles (AuNPs) to actively target human endometriosis …
Background: Abdominal wall endometriosis (AWE) is a rare but debilitating condition, often occurring in surgical scars after Caesarean sections. It is characterized by cyclic pain and a palpable mass, significantly …
Endometriosis is a widespread estrogen-driven condition causing pelvic pain and infertility in women. This disease shares five features with cancer: Intrinsic growth signals, insensitivity to antiproliferative signals, impaired apoptosis, induction …
Endometriosis is a condition that manifests through chronic pelvic pain and infertility. Current therapeutic options do not provide complete relief and may result in undesirable side effects.
Endometrial regeneration is a cornerstone of reproductive health, with the extracellular matrix (ECM) playing a pivotal role in tissue repair, regeneration, and fertility restoration. Dysregulated ECM remodeling is at the …
Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …